ClinicalTrials.gg
CompletedNCT02388464Updated Sep 17, 2015

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

A Phase 1 interventional study of MTP-131 and MTP-131 in Congestive Heart Failure, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in Bulgaria. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-09-17.

Sponsored by Stealth BioTherapeutics Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Heart Failure with a site in Bulgaria — 18 open to participants now, 22 under way, 12 of them phase 3. Heart Failure · Bulgaria.

Enrollment
74th of 76
36 · median 617
Started
2014
with 4 others
Phase 1
4 of 82
none open now
Registered
20th of 82
by date
Lead sponsor
3 of 82
Stealth BioTherapeutics Inc.

Among the 82 studies in Heart Failure with a site in Bulgaria, this one is the 74th largest by enrollment of the 76 interventional ones that give a count, is one of 5 that started in 2014, is one of 4 in phase 1, and was the 20th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 82 studies in Heart Failure with a site in Bulgaria are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Heart Failure with a site in Bulgaria, or all of them as a file.
02

Study summary

This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to evaluate the safety, tolerability, and pharmacokinetics of escalating single intravenous infusion doses of Bendavia™ (MTP-131).

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

Keywords

  • Congestive Heart Failure
  • Bendavia™
  • MTP-131
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic ischemic or non-ischemic cardiomyopathy of at least 6 months duration from the time of the initial diagnosis.
  • ≤35% by 2-D echocardiogram.
  • Diagnosis of Class II or III HF for a minimum of 6 months prior to the Screening Visit.
  • HF is considered to be stable and no hospitalization for HF has occurred within the previous 3 months prior to the Screening visit.
  • Treatment with appropriate pharmacologic therapy for HF including, but not limited to, angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB), and an evidence-based beta blocker for the treatment of HF (i.e. carvedilol, bisoprolol, or extended-release metoprolol).
  • Dose and dose regimen of pharmacologic treatments for HF must be stable for a minimum of 1 month prior to the Screening Visit.
  • Females of must have a negative serum pregnancy test at the Screening Visit and Day 1.

Exclusion criteria

Exclusion Criteria:

  • LV end-diastolic dimension (LVEDD), by the same method as qualifying , is >80 mm or LVEDD indexed to body surface area is >0.45.
  • Unstable angina pectoris within 1 month before initiation of screening procedures. Unstable angina is defined as the occurrence of chest pain more frequently than usual, pain at rest or upon minimal exertion, or protracted episodes of pain without any discernible trigger, and/or chest pain that persists despite use of vasodilatory therapy (e.g., nitroglycerin).
  • Coronary or peripheral artery revascularization procedure within 2 months prior to the Screening Visit.
  • An acute myocardial infarction within 3 months prior to the Screening Visit.
  • Placement of an automated implantable cardioverter defibrillator (AICD) or any hardware associated with resynchronization therapy.
  • Atrial fibrillation at the Screening or Baseline Visits.
  • Uncontrolled hypertension defined as a systolic blood pressure (BP) > 180 mm Hg or a diastolic BP >110 mm Hg on at least 2 consecutive readings.
  • Requirement for valve or other cardiac surgery
  • Cardiac surgery or valvuloplasty within 2 months prior to the Screening Visit.
  • General surgery within 1 month prior to the Screening Visit
  • Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic left ventricular aneurysm.
  • Cerebrovascular accident or within 3 months prior to the Screening Visit.
  • Estimated (eGFR) \<40 mL/min, using the Modification of Diet in Renal Disease (MDRD) Study equation
  • Serologic evidence of or C infection.
  • Known acquired immunodeficiency syndrome or -positive status, or diagnosis of immunodeficiency.

    • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: MTP-131

  • Experimental
    Intermediate dose

    Drug: MTP-131

  • Experimental
    High dose

    Drug: MTP-131

  • Experimental
    Placebo

    Drug: Placebo

Interventions

  • MTP-131 (low dose) administered as single intravenous infusion over 4 hours

  • MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours

  • MTP-131 (high dose) administered as single intravenous infusion over 4 hours

  • DrugPlacebo

    Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Time frame: Assessed up to Day 7

Secondary outcomes

  1. Left ventricular ejection fraction assessed by 2-D echocardiography

    Time frame: Assessed up to 24 hours post-infusion start

07

Study locations

1 site
  • Sevlievo, Gabrovo, Bulgaria
08

References and documents

Publications

  • Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE, Sabbah HN. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017 Dec;10(12):e004389. doi: 10.1161/CIRCHEARTFAILURE.117.004389. PubMed 29217757 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Apr 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2015
First posted
Mar 17, 2015
Start
Jul 2014
Primary completionActual
Apr 2015
CompletionActual
Jun 2015
Last update
Sep 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02388464
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Jul 2014
Primary completion
Apr 2015
Completion
Jun 2015
Last update
Sep 17, 2015

Study contacts

Jim Carr, PharmD
study director · Stealth BioTherapeutics Inc.
Sotir Marchev, MD,PhD, FESC
principal investigator · Bulgaria

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion